Skip to main content
. 2020 Feb 9;5(1):e000391. doi: 10.1136/tsaco-2019-000391

Table 1.

Matched cohort demographics and outcomes

Covariate, % (n) or mean (SE) Dronabinol cases (n=33) Non-dronabinol controls (n=33) P value
Males 75.8 (25) 69.7 (23) 0.59
Mean age, years 29.9 (1.7) 30.0 (1.7) 0.90
Mean injury severity score 12.8 (1.3) 15.7 (2.0) 0.11
Cause of injury
 Vehicular crash 45.5 (15) 58.5 (16) 1.00
 Fall cause 30.3 (10) 33.3 (11) 1.00
 Other cause 24.2 (8) 18.2 (6) 1.00
Surgical intervention 63.6 (21) 63.6 (21) 1.00
Injury location/region
 Head injury 48.5 (16) 57.6 (19) 0.58
 Chest injury 39.4 (13) 42.4 (14) 1.0
 Abdominal injury 18.2 (6) 30.3 (10) 0.39
 Spinal injury 27.3 (9) 54.6 (18) 0.01
 Extremity 75.8 (25) 54.6 (18) 0.12
Pre-injury marijuana user 57.6 (19) 12.1 (4) 0.002
Pre-injury opioid user 12.1 (4) 3.0 (1) 0.25
Pain management contract 0 (0) 0 (0) NA
Median (SE) hours to ‘post’period 54.5 (9.6) 48 (0) 0.11
Mean baseline* MME 168.8 (18.2) 129.6 (15.7) 0.07
Mean baseline* pain 5.8 (0.3) 4.9 (0.3) 0.05
Mean hospital LOS, days 9.3 (1.1) 11.4 (1.5) 0.17
Mean ICU LOS, days 2.2 (0.5) 4.0 (1.1) 0.12

P value: McNemar's test for categorical variables, paired t-test for continuous variables, Wilcoxon rank sum test for medians. The values in bold indicate statistical significance.

*Baseline: 48 hours before dronabinol (cases) and 0–48 hours from admission (controls).

ICU, intensive care unit; LOS, length of stay; MME, morphine milligram equivalents.